To All, Looks like SI is finally working again. I couldn't get on for several hours, and I had some interesting things to say for a change.
1. AMAT's warnings were much worse than expected. Of course, I expected them. <G> Not only are earnings in the toilet, but orders are even worse. The stock barely reacted, as reality has nothing to do with tech stocks right now.
2. Ligand will get priority FDA review of its Panretin gel for Kaposi's Sarcoma. This one also has orphan status, which I think means it gets extra pudding. <G> Seriously, that means no generics are allowed for a longer period of time. With the priority review, the FDA has to rule within 6 months. The fundamental story just gets better for this company. The stock price still stinks. Major league buy.
3. Cell Genesys has seen remarkable early results for treating HIV with its gene therapy. Cheap stock, lots of product.
4. I wrote the piece for The Internet Financial Connection this week, which should appear on Wednesday. Most of it is same old, same old, though I did recommend some long internet stocks in a paired trade against long IIX puts.
Good luck,
MB |
